The PDE-5 inhibitor produced a clinically relevant reduction in the asymmetry in temperature between the affected and unaffected feet in CRPS, most likely due to the restoration of blood flow in the affected extremity. The gene discussed is PDE5A; the disease is complex regional pain syndrome.